Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL

被引：0
|
作者：
Yin, C [1 ]
Luthra, R [1 ]
Cortes, J [1 ]
Reeves, N [1 ]
Hayes, K [1 ]
Glassman, A [1 ]
Kantarjian, H [1 ]
Jones, D [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2004年 / 6卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
H8
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [21] BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia
    Gruenebach, Frank
    Mirakaj, Valbona
    Mirakaj, Valdete
    Mueller, Martin R.
    Bruemmendorf, Tim
    Brossart, Peter
    CANCER RESEARCH, 2006, 66 (11) : 5892 - 5900
  • [22] BCR-ABL RNA IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
    SHTIVELMAN, E
    GALE, RP
    DREAZEN, O
    BERREBI, A
    ZAIZOV, R
    KUBONISHI, I
    MIYOSHI, I
    CANAANI, E
    BLOOD, 1987, 69 (03) : 971 - 973
  • [23] BCR-ABL Mutations in Chronic Myeloid Leukemia
    Ernst, Thomas
    La Rosee, Paul
    Mueller, Martin C.
    Hochhaus, Andreas
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (05) : 997 - +
  • [24] A pyrosequencing method for quantitation of mutated BCR-ABL transcripts in chronic myelogenous leukemia patients with imatinib resistance
    Yin, CC
    Luthra, R
    Galbincea, I
    Cortes, J
    Jones, D
    LABORATORY INVESTIGATION, 2005, 85 : 258A - 259A
  • [25] A pyrosequencing method for quantitation of mutated BCR-ABL transcripts in chronic myelogenous leukemia patients with imatinib resistance
    Yin, CC
    Luthra, R
    Galbincea, J
    Cortes, J
    Jones, D
    MODERN PATHOLOGY, 2005, 18 : 258A - 259A
  • [26] The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia
    Wang, LH
    Knight, K
    Lucas, C
    Clark, RE
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 235 - 239
  • [27] Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene
    J J W M Janssen
    A Hochhaus
    J W van Oostveen
    Q Waisfisz
    G J Schuurhuis
    G J Ossenkoppele
    Leukemia, 2004, 18 : 1020 - 1021
  • [28] Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene
    Janssen, JJWM
    Hochhaus, A
    van Oostveen, JW
    Waisfisz, Q
    Schuurhuis, GJ
    Ossenkoppele, GJ
    LEUKEMIA, 2004, 18 (05) : 1020 - 1021
  • [29] Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia
    Stanek, E.
    Aubert, R. E.
    Sanders, C.
    Frueh, F. W.
    Yao, J.
    Epstein, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.
    Teitelbaum, A. H.
    Henk, H. J.
    Bollu, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345